A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Condition: Metastatic Uveal Melanoma Intervention: Drug: DYP688 Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 10, 2022 Category: Research Source Type: clinical trials
